High Growth Tech Stocks in Asia Featuring 3 Promising Picks
Amid escalating geopolitical tensions and trade-related concerns, Asian markets have shown resilience, with China's recent trade agreements providing a glimmer of optimism despite ongoing deflationary pressures. In this dynamic environment, identifying high-growth tech stocks in Asia involves evaluating companies that can leverage technological innovation and strategic positioning to navigate economic challenges and capitalize on emerging opportunities.
Name
Revenue Growth
Earnings Growth
Growth Rating
Suzhou TFC Optical Communication
29.78%
30.32%
★★★★★★
Shengyi Electronics
22.99%
35.16%
★★★★★★
Fositek
26.71%
33.90%
★★★★★★
Shanghai Huace Navigation Technology
24.44%
23.48%
★★★★★★
Range Intelligent Computing Technology Group
27.31%
28.63%
★★★★★★
eWeLLLtd
24.95%
24.40%
★★★★★★
PharmaResearch
24.47%
25.73%
★★★★★★
Nanya New Material TechnologyLtd
22.72%
63.29%
★★★★★★
Global Security Experts
20.56%
28.04%
★★★★★★
JNTC
54.24%
87.93%
★★★★★★
Click here to see the full list of 488 stocks from our Asian High Growth Tech and AI Stocks screener.
We're going to check out a few of the best picks from our screener tool.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Celltrion, Inc. is a biopharmaceutical company focused on developing, producing, and selling therapeutic proteins for oncology treatments with a market capitalization of ₩35.78 trillion.
Operations: The company primarily generates revenue from its biopharmaceutical segment, which accounts for ₩6.18 trillion. It also earns from chemical drugs, contributing ₩523.71 million to its total revenue.
Celltrion, a key player in the biotech sector, is making significant strides with its FDA-approved biosimilar YUFLYMA®, enhancing patient access through strategic price adjustments and expanded interchangeable designations. The company's commitment to innovation is further underscored by a robust 27.2% forecasted annual earnings growth and an aggressive share repurchase program, signaling strong future prospects. Moreover, recent clinical trials highlight potential safety advantages of their products over competitors', positioning Celltrion favorably within the high-growth biotechnology landscape in Asia.
Click to explore a detailed breakdown of our findings in Celltrion's health report.
Assess Celltrion's past performance with our detailed historical performance reports.
Simply Wall St Growth Rating: ★★★★★☆
Overview: China Ruyi Holdings Limited is an investment holding company involved in content production and online streaming across Mainland China, Hong Kong, Europe, and other international markets, with a market capitalization of approximately HK$33.99 billion.
Operations: China Ruyi Holdings Limited primarily generates revenue through its online streaming and gaming businesses, which contribute CN¥3.51 billion, followed by content production at CN¥127.04 million.
Amid a challenging fiscal year, China Ruyi Holdings has demonstrated resilience with strategic financial maneuvers, including a substantial fixed-income offering of HKD 2.341 billion and aggressive private placements aimed at bolstering its capital structure. Despite reporting a net loss of CNY 190.53 million for 2024, contrasting sharply with the previous year's profit, the company is poised for recovery with projected revenue growth at an impressive rate of 27.4% annually. This outlook is supported by recent corporate actions such as share repurchases and convertible bond issues, underscoring management's commitment to navigating through volatile markets while maintaining focus on long-term growth strategies in high-tech sectors across Asia.
Click here and access our complete health analysis report to understand the dynamics of China Ruyi Holdings.
Gain insights into China Ruyi Holdings' past trends and performance with our Past report.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on the research and development of antibody and protein medicine products across China, the United States, and internationally, with a market cap of HK$132.62 billion.
Operations: The company generates revenue primarily from its biotechnology segment, amounting to CN¥9.42 billion.
Innovent Biologics has recently made significant strides in the biopharmaceutical field, particularly with its innovative cancer treatments. The company's recent regulatory successes include multiple Breakthrough Therapy Designations (BTDs) and Fast Track Designations (FTDs) from both U.S. and Chinese health authorities for its novel PD-1/IL-2a-bias bispecific antibody fusion protein, IBI363. These designations, which aim to expedite the development and review process for promising drugs, highlight Innovent's commitment to addressing critical unmet medical needs in oncology. Moreover, the acceptance of New Drug Applications (NDAs) by China's NMPA for other advanced therapies underscores Innovent's potential to impact global health outcomes significantly.
Get an in-depth perspective on Innovent Biologics' performance by reading our health report here.
Learn about Innovent Biologics' historical performance.
Embark on your investment journey to our 488 Asian High Growth Tech and AI Stocks selection here.
Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSE:A068270 SEHK:136 and SEHK:1801.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Cyberway Product Innovation Platform: Empowering Enterprise Innovation Processes and Building Exceptional Product Strength
GUANGZHOU , June 22, 2025 /PRNewswire/ -- In the fiercely competitive FMCG market, only efficient innovation can create a true competitive edge. As consumer preferences change rapidly and the market environment remains uncertain, how can companies precisely identify needs, execute efficiently, and continuously optimize their strategies? The Cyberway Product Innovation Platform empowers FMCG enterprises to achieve sustainable growth by providing powerful capabilities in pre-planning insight, in-process control, and post-launch analytics—ultimately enabling the development of exceptional product strength. Before: AI-Powered Foresight for Accurate Market Opportunity Detection AI Opportunity Discovery: Real-time industry data, user behavior, and competitor insights are captured to automatically identify blue ocean markets and unmet needs—fueling inspiration for new product planning. Accelerate Opportunity Capture: Shorten market research cycles and improve speed and accuracy of opportunity identification. AI-Driven Product Definition: Using opportunity and competitor analysis, combined with internal product knowledge bases, the system intelligently generates product concepts, optimizes configurations, and refines packaging and formulas. Agile Response: Ensure product design closely aligns with market needs and competition, allowing rapid focus on core value and improving product-market fit. End-to-End User Demand Management: A comprehensive demand management framework tracks records, statuses, and feedback, aggregating omnichannel voice of customer with AI to identify high-value & Accurate: By realizing and verifying demand in closed-loop cycles, continuously refine product performance, minimize resource waste, and pave the way for the next breakout product. During: Efficient Execution to Deliver Outstanding Products Scientific Project Management System: Integrates visual dashboards, all-in-one workbenches, and real-time notifications via Feishu, WeCom, and DingTalk for full project transparency and synchronized decision-making across teams. Core Value: Reduce communication overhead, improve collaboration efficiency, and prevent project delays. Standardized Project Workflow: Based on industry templates and task libraries, enabling tiered and structured project management tailored to channel requirements. Flexible Control: Guarantees high-quality delivery while allowing adaptive workflows, ensuring key tasks succeed the first time. Cross-Functional Online Collaboration: Integrates marketing, go-to-market, and product workflows to shorten timelines. Interlocked nodes require mutual confirmation to ensure stability and avoid cost waste. Key Feature: Enables synergistic cooperation across departments for performance greater than the sum of its parts. AI Marketing: Tracks competitor strategies and social trends in real time, dynamically generating targeted content and pricing strategies using internal knowledge. Efficient & Agile: Accelerates creative production and drives an integrated "strategy-content-pricing" engine for rapid market response. Online Knowledge Repository: A dedicated enterprise R&D knowledge base aggregating key data such as risk warnings, solutions, and technical documentation. Significant Boost: Empowers faster troubleshooting and prevents redundant errors in R&D. Comprehensive Quality Control System: Embeds IPD checkpoints and technical reviews to govern key milestones; incorporates risk management for prevention, monitoring, and post-analysis. Ultimate Goal: Ensure high-quality project delivery while minimizing potential risks. After: Data-Driven Innovation Strategy Optimization Project Review: Compare project baselines with actual execution to deeply analyze quality, timeline, and cost performance. Deeper Insights: Identify key factors that influence project success. Go-to-Market Tracking: Monitor GMV trends across e-commerce platforms, VOC on social media, and promotional campaign outcomes to pinpoint growth opportunities and risks, driving agile strategy iteration. Advanced Capabilities: Fuel product iteration and innovation, providing a core foundation for the next-generation breakout product. Data Asset Management: Leverages delivery data and gate review points to auto-update master product data, creating a unified view with field supplementation and relationship validation. Long-Term Value: Enables full-lifecycle product data management, enhancing both data quality and business utility. The Cyberway Product Innovation Collaboration Platform is a powerful enabler for FMCG enterprises to enhance product innovation with AI, reduce waste, shorten R&D cycles, and create market bestsellers. From ideation to launch and ongoing optimization, the platform empowers excellence at every stage—allowing businesses to stand out in an intensely competitive landscape. We look forward to partnering with more brands to explore new ways of innovation and co-create the next market blockbuster! Website: Email：Marketing@ View original content: SOURCE Cyberway Information Technology Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
The world's richest added $2B in 2025 — Use these 6 clever strategies to grow your own fortune fast
The 39th annual Forbes billionaire list is out, and it's a jaw-dropper. The number of billionaires has surged to 3,028, a record. Together, these individuals hold a staggering US$16.1 trillion in wealth, up US$2 trillion from last year. More than 100 Forbes reporters dove deep into financial data to assemble this list, including stocks, investments and cash flows, along with more eccentric billionaire purchases such as yachts, art collections and even dinosaur bones. The U.S. holds first place with 902 billionaires, followed by China and Hong Kong (516), and India (205). The wealthiest are led by Elon Musk, with US$342 billion, followed by Mark Zuckerberg at US$216 billion, and Jeff Bezos at US$215 billion. Rounding out the top 10 are heavyweights including Warren Buffett, Larry Ellison and LVMH's Bernard Arnault. In short, the billionaire game is booming. Want in on the action? You may want to take notes from the world's richest. According to Forbes senior editor Chase Peterson-Withorn, the rise in billionaire wealth isn't just about tech giants and luxury brands; it's about how much power these individuals hold. 'It's a great time to be a billionaire,' Peterson-Withorn recently told NPR's Morning Edition. To arrive at these figures, Forbes determines the annual list by tracking every asset, minus any debts. And if a billionaire doesn't spill the beans themselves, Forbes digs through legal filings, offshore accounts and leaks to get the scoop. This year, 288 new names have joined the ranks of the world's billionaires. Among them are celebrities such as Bruce Springsteen (US$1.2B), Arnold Schwarzenegger (US$1.1B) and Jerry Seinfeld (US$1.1B). Also on the list are crypto mogul Justin Sun (US$8.5B), along with AI entrepreneurs from companies including Anthropic, CoreWeave and DeepSeek. The food world is well-represented, with moguls behind popular chains such as Cava, Chipotle, Jersey Mike's and Zaxby's. Topping the list of newcomers is Marilyn Simons, who inherited a US$31 billion fortune following the passing of her husband, hedge fund legend Jim Simons, in 2024. But not every billionaire had a good year. Over 100 names dropped off the 2024 list, no longer rich enough to make the cut. Some notable exits include Lisa Su, CEO of semiconductor giant AMD, Sara Liu, co-founder of server company Supermicro and Nicholas Puech, heir to the Hermès luxury brand, who says his fortune has disappeared. "A lot of billionaires don't have great reputations these days," Peterson-Withorn said, "but on the other hand, they're more powerful than ever." There may be some backlash against the billionaires on the Forbes list, but that doesn't mean there aren't some lessons to be learned about investing from some of the world's wealthiest individuals. You don't need unlimited wealth to invest like a billionaire. The ultra-wealthy use strategy, smart decisions, as well as balancing risk and reward to get ahead. Here's how you can do the same. Ultra-high-net individuals spread their wealth across everything from stocks and real estate to private equity and bonds; in other words, diversifying is key. This reduces risk while increasing the chances for steady, long-term growth. For regular investors, diversifying with exchange-traded funds (ETFs) or mutual funds covering domestic and international markets is a good start. And don't forget bonds for stability during market ups and downs. Real estate is another billionaire favourite. While they may invest in expensive commercial or luxury residential properties, you can get in the game through real estate investment trusts (REITs) — here are the best in Canada. The super wealthy don't chase trends — they think decades ahead. Want to build wealth? Max out contributions to retirement accounts such as TFSAs and RRSPs. These tax-advantaged accounts let your money compound over time. While billionaires love high returns, they're pros at managing risk, and you can do the same by building an emergency fund. Having liquid cash in your account ensures you're not forced to sell investments during a market slump. A simple buffer can keep you secure while you wait for the market to bounce back. Wealthy investors leverage technology by using AI-powered predictions, algorithmic trading and cutting-edge tools to stay ahead. You don't need billions to tap into this power. Robo-advisors can help automate your portfolio management based on your goals to help you make smarter investment decisions — here are the best robo-advisors in Canada. Many high-net-worth individuals invest in alternative assets such as commodities and fine art to round out their portfolios. Commodities such as gold and silver can be hedges against inflation and market volatility. And while not highly liquid, collectibles, artwork or vintage cars can offer diversification and the potential for substantial returns. Investing like a billionaire isn't about having a billion-dollar portfolio. It's about following the basics, diversifying across asset classes and thinking long-term. Leverage technology, manage your risks and stay patient. Whether it's real estate, stocks or commodities, billionaire strategies can help set you on the path to financial success. Of course, always consult a financial advisor and do the proper research before you dive into any new investment. 1. Forbes: Forbes World's Billionaires List 2025: The Top 200, by Chase Peterson-Withorn (Apr 1, 2025) 2. NPR: More billionaires than ever ranked in Forbes' annual list. Here are the top 10, by A Martínez, Obed Manuel (Apr 1, 2025) This article provides information only and should not be construed as advice. It is provided without warranty of any kind. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
The Sad Case of The World's Youngest-Ever Alzheimer's Diagnosis
In 2023, neurologists at a memory clinic in China diagnosed a 19-year-old with what they believed to be Alzheimer's disease – making him the youngest person ever to be diagnosed with the condition. The teen first began experiencing memory decline around age 17, with symptoms worsening over time. Brain scans revealed shrinkage in the hippocampus, a region involved in memory, while his cerebrospinal fluid showed biomarkers consistent with Alzheimer's – the most common form of dementia. Although usually associated with older age, early-onset cases of Alzheimer's (those occurring in individuals under age 65) represent up to 10 percent of all diagnoses. Almost all Alzheimer's patients under the age of 30 can have their disease explained by pathological gene mutations, classifying them as having familial Alzheimer's disease (FAD). The younger a person is when they receive a diagnosis, the more likely it is caused by an inherited faulty gene. However, researchers at Beijing's Capital Medical University were unable to find any of the usual mutations responsible for the early onset of memory loss, nor any suspect genes, after conducting a genome-wide search. Before this diagnosis in China, the youngest patient with Alzheimer's was 21 years old. They carried the PSEN1 gene mutation, which causes abnormal proteins to build up in the brain, forming clumps of toxic plaques, a common feature of Alzheimer's. Cases like this one pose something of a mystery. None of the 19-year-old's family had a history of Alzheimer's or dementia, making it hard to categorize it as FAD, yet the teenager had no other diseases, infections, or head trauma that could explain his sudden cognitive decline either. Two years before being referred to the memory clinic, the teenage patient began struggling to focus in class. Reading also became difficult and his short-term memory declined. Oftentimes, he couldn't remember events from the day before, and he was always misplacing his belongings. Ultimately, the cognitive decline became so bad, the young man was unable to finish high school, although he could still live independently. A year after being referred to the memory clinic, he showed losses in immediate recall, short-delay recall after three minutes, and long-delay recall after 30 minutes. The patient's full-scale memory score was 82 percent lower than that of peers his own age, while his immediate memory score was 87 percent lower. Long-term follow-up is needed to support the young man's diagnosis, but his medical team said at the time the patient was "altering our understanding of the typical age of onset of AD." "The patient had very early-onset AD with no clear pathogenic mutations," neurologist Jianping Jia and colleagues wrote in their study, "which suggests that its pathogenesis still needs to be explored." The case study, published in February 2023, just goes to show that Alzheimer's doesn't follow a single pathway, and is much more complex than we thought, emerging via numerous avenues with varying effects. In a statement to the South China Morning Post, the neurologists who described the patient's case argued that future studies should focus on early-onset cases to further improve our understanding of memory loss. "Exploring the mysteries of young people with Alzheimer's disease may become one of the most challenging scientific questions of the future," they said. The study was published in the Journal of Alzheimer's Disease. An earlier version of this article was published in February 2023. Compound That Turns People Yellow Could Protect Against Malaria Scientists May Have Finally Figured Out How Bats Avoid Cancer 'Off Switch' in The Brain to Stop Binge Drinking Discovered in Mice
